Description  Claims  Drawing  Cited references 

WO2010149769A   [0019]  [0196] 
EP2015052242W   [0183]  [0196] 
EP2015052239W   [0196] 
WO2013189771A   [0197] 
WO2010149769A1   [0345] 
WO2013189771A1   [0345] 

The Merck Manual of Diagnosis and Therapy   [0005]  [0011] 
Drugs of the future   [0023] 
Arthritis & Rheumatology   [0024] 
The Merck Manual of Diagnosis and Therapy   [0071]  [0072]  [0073]  [0075]  [0078] 
2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative   [0345] 
Enzymatic Determination of Total Serum Cholesterol   [0345] 
HDL-C: Role as a risk modifier   [0345] 
Thematic review series: The Immune System and Atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?   [0345] 
Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease   [0345] 
Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib   [0345] 
Development of a new microparticle-enhanced turbidimetric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range   [0345] 
Rheumatoid arthritis measures: Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI)   [0345] 
Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge   [0345] 
Cardiovascular disease - the silent killer in rheumatoid arthritis   [0345] 
Low Paraoxonase Activity Predicts Coronary Events in the Caerphilly Prospective Study   [0345] 
Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention   [0345] 
Search for an Optimal Atherogenic Lipid Risk Profile: From the Framingham Study   [0345] 
Changes in Lipoproteins Associated With Methotrexate Therapy or Combination Therapy in Early Rheumatoid Arthritis: Results From the Treatment of Early Rheumatoid Arthritis Trial   [0345] 
CRP-Marker or Maker of Cardiovascular Disease?   [0345] 
Back to the Future: Oral targeted therapy for RA and other autoimmune diseases   [0345] 
JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease   [0345] 
Development and validation of a particle-enhanced turbidimetric immunoassay for C-reactive protein   [0345] 
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events   [0345] 
Measurement of low-density-lipoprotein cholesterol in serum: a status report   [0345] 
Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm   [0345] 
Low-Density-Lipoprotein Particle Size Predicts a Poor Outcome in Patients with Atherothrombotic Stroke   [0345] 
The Merck Manual of Diagnosis and Therapy   [0345] 
Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate   [0345] 
Greene's Protective Groups in Organic Synthesis   [0345] 
Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD   [0345]